

EBV May be Linked to Throat Cancer; The CBCD Reviews the Medical Evidence

EBV infection has a relationship with certain subtypes of ESCC (esophageal squamous cell carcinoma). (1)

ROCHESTER, NEW YORK, UNITED STATES OF AMERICA, January 18, 2016 /EINPresswire.com/ --

“Infected with the EBV virus? We recommend taking [Gene-Eden-VIR](#) or [Novirin](#).” – Greg Bennett, CBCD

Most people associate the Epstein Barr Virus (EBV) with infectious mononucleosis (Mono, also known as “the kissing disease”). However, studies are showing that EBV is also linked to esophageal cancer, which is “the eighth most prevalent malignant tumor and the sixth leading cause of cancer mortality throughout the world.” (1) One review of the medical literature found “EBV in 8.3% (5/60) of cases by PCR. In Germany, Awerkiew et al. confirmed the association. EBV DNA was detected in 35% of squamous cell carcinomas and 36% of adenocarcinomas by nested PCR, which is more sensitive than conventional PCR. The most convincing report is from Shantou, located in South China. EBV EBER and LMP-1 proteins were identified in 10 (6.1%) EC specimens by both ISH and IHC.” (1) In other words, many studies found EBV DNA in throat cancer tumors.

In addition, one case study mentioned the following: A 55 year old man presented with “two giant (bleeding) ulcers in the esophagus and stomach, wherein pathological examination and immunohistochemical staining revealed that the two lesions displayed the same form of poorly differentiated carcinoma with a dense lymphoid stroma and diagnosed as LELC ...” (2) The study concluded that “the association of esophageal LELC and EBV ... all need to be further studied.” (2)



therefore recommends that individuals infected with EBV take Gene-Eden-VIR or Novirin. The formula of these natural antiviral products was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Gene-Eden-VIR and Novirin formula is effective against EBV and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, "individuals infected with EBV...reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR." (3) The study authors also wrote that, "We observed a statistically significant decrease in the severity, duration, and frequency of symptoms." (3) In addition, this natural antiviral was recently proven to reduce mental and physical fatigue in a post-marketing clinical study that followed FDA guidelines.

Both products can be ordered online on the Gene-Eden-VIR and Novirin websites, here:

<http://www.gene-eden-vir.com>

and

<http://www.novirin.com>

Gene-Eden-VIR and Novirin are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

EBV chronically infects about 95% of the adult population, with virus usually present in B cells in a latent stage. (4) However, not everyone infected will develop cancer. According to Dr. Polansky, and his book "Microcompetition with Foreign DNA and the Origin of Chronic Disease," people develop cancer when the number of latent viruses passes a certain threshold. One of the reasons for an increase in the number of latent viruses is a weak immune system.

The CBCD offers a free download of Dr. Polansky's book to those who are interested in reading it.

<http://www.cbcd.net/Book.php>

Dr. Fujiwara wrote that people with a chronic EBV infection face a poor outcome. In addition to constant symptoms of Mononucleosis, they can also develop "life-threatening complications including hemophagocytic lymphohistiocytosis (a condition that causes the immune system to attack the body's own tissues), organ failure, and malignant lymphomas (cancer)." (4) Dr. Fujiwara is from the Department of Infectious Diseases, National Research Institute for Child Health and Development in Tokyo, Japan.

What standard treatments are available for EBV infections?

"A few antiviral drugs are available that were shown to inhibit EBV replication in cell culture. These drugs include the acyclic nucleoside analogues aciclovir, ganciclovir, penciclovir, and their respective prodrugs valaciclovir, valganciclovir and famciclovir, the acyclic nucleotide analogues cidofovir and adefovir, and the pyrophosphate analogue foscarnet. However, clinical studies have shown that these drugs are mostly ineffective in humans." (3) There are also natural antiviral products that studies show

to be safe and effective in reducing EBV symptoms. Two of these products are Gene-Eden-VIR and Novirin.

In light of the above information, the CBCD recommends that individuals infected with the latent Epstein Barr Virus (EBV) take Gene-Eden-VIR or Novirin.

Find us on Facebook here: <https://www.facebook.com/GeneEdenVIR>

Follow us on Twitter here: @HananPolansky

All orders of these products are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1) Xu W1, Liu Z1, Bao Q1, Qian Z1. "Viruses, Other Pathogenic Microorganisms and Esophageal Cancer." *Gastrointest Tumors*. 2015 May;2(1):2-13.

(2) Jinru Xue,1,* Haixin Yu,1,* Jidong Yan,1 Na Ren,1 Yi Yang,2 Xueju Wang,3 and Yan Wang1 "Non-Epstein-Barr virus-associated double primary lymphoepithelioma-like carcinoma of the esophagus and stomach: a case report and literature review" *Int J Clin Exp Med*. 2015; 8(6): 10051–10057

(3) Polansky H, Itzkovitz E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. *Pharmacology & Pharmacy*, 2013, 4, 1-8<http://dx.doi.org/10.4236/pp.2013.46A001>

(4) Fujiwara S1, Kimura H, Imadome K, Arai A, Kodama E, Morio T, Shimizu N, Wakiguchi H. Current research on chronic active Epstein-Barr virus infection in Japan. *Pediatr Int*. 2014 Apr;56 (2):159-66.

Greg Bennett
CBCD
585-250-9999
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.



